Vigabatrin: adverse event reports filed with FDA

3,664

reports as suspect product

0% of all reports · about 164 a year

263

reports, 12 months to June 2026

491 in the 12 months before

80.6%

marked serious by the reporter

78.1% across the class

10.1%

record death among outcomes, as reported

369 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Vigabatrin reports recording the termmedian drug in anti-epileptic agent

1. Seizurea fit or convulsion17.9%657
2. Drug ineffectivethe medicine did not work as expected15.8%579
3. Adverse eventan unwanted medical event, type not specified6.7%245
4. Deaththe patient died; cause not stated by this term5.6%206
5. Off label useused for a purpose or in a way not on the label5.2%190
6. Hospitalisationadmission to hospital5.2%189
7. Magnetic resonance imaging head abnormal5%183
8. Drug resistance4.1%152
9. Epilepsy4.1%150
10. Product use issuea problem in how the product was used3.5%129
11. Multiple-drug resistance3.5%128
12. Status epilepticus3.2%116
13. Somnolencedrowsiness2.9%105
14. Condition aggravatedthe condition being treated got worse2.8%101
15. Vomitingbeing sick2.4%89
16. Toxicity to various agentspoisoning or toxic effect of one or more substances2.4%88
17. Pneumonialung infection2.4%87
18. Product dose omission issuea dose was missed2.3%86
19. Treatment failurethe treatment did not work2.1%78
20. Therapy non-responderthe treatment did not work1.7%64
21. Encephalopathy1.6%58
22. Infantile spasms1.5%56
23. Therapy interrupted1.4%52
24. Drug interactionan interaction between medicines1.4%50
25. Neurotoxicity1.3%46
26. Pyrexiafever1.3%46
27. Therapeutic product effect incomplete1.2%44
28. Retinal disorder1.2%43
29. Magnetic resonance imaging brain abnormal1.1%41
30. Respiratory failurethe lungs could not supply enough oxygen1%38

Top 30 of 410 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 23 drugs in the anti-epileptic agent class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 269,757 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 64.7% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 3,664 reports.

Drugs most often listed in the same reports

Other products listed in reports where Vigabatrin is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the anti-epileptic agent class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Vigabatrin as a suspect or interacting product; reports listing it only as a concomitant medication (1,046) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.